Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02767362 · ClinicalTrials.gov registry record · Early Phase 1

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

A Early Phase 1 study of Endometrial Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT02767362: Completed Early Phase 1 study of Endometrial Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT02767362 is a Early Phase 1 study of Endometrial Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 24 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02767362, a Early Phase 1 study of Endometrial Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer.

Primary Outcome

Measurement of the change in tumor proliferation as measured by Ki67 immunohistochemical staining after 2-4 weeks of treatment with atorvastatin. For visual comparisons of pre- and post-treatment measures, informative plots will be generated. For statistical comparisons of pre- and post-treatment measures absolute difference scores will be created. An absolute difference score is the subtraction of a post-treatment measurement from a pre-treatment measurement. The nonparametric Wilcoxon signed-r

Conditions Studied

Interventions

  • DRUG Atorvastatin

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-11
Est. Completion 2019-09-26
Phase Early Phase 1

What the finished NCT02767362 record still lists

NCT02767362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin is the first listed.

NCT02767362 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02767362 about?

NCT02767362 is a clinical study titled "A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium". This is a preoperative window, phase 0 study of short-term atorvastatin treatment in obese women who are to undergo surgical staging for endometrial cancer.

What is the current status of trial NCT02767362?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2015-11. Estimated completion is 2019-09-26.

What conditions does trial NCT02767362 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT02767362?

The interventions under investigation include: Atorvastatin (DRUG).

Who is sponsoring clinical trial NCT02767362?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02767362 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02767362's enrollment target sits among peer trials

24 162nd of 181 higher than 19 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02767362, the US trial registry maintained by the National Library of Medicine. NCT02767362 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.